SABS SAB Biotherapeutics: Price-to-Projected Revenue Ratio
SAB Biotherapeutics (SABS) efficiency is based on partnerships with external laboratories while maintaining control over bio-assets. The GURU.Markets service features a line chart where the forward revenue multiple 1668.60 records a new level. This confirms the platform's flexibility in creating antibodies against diabetes, although financial stability remains vulnerable due to high production costs and potential FDA delays in final testing.
Comprehensive metric breakdowns and analytics for SAB Biotherapeutics Inc (SABS)
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- company liabilities and liquidity data:
Total Debt to Equity Ratio SAB Biotherapeutics|SABS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital SAB Biotherapeutics|SABS - Company Debts|Debts to Book Capitalization SAB Biotherapeutics Inc|SABS - Long-Term Debt Volume|Company Short-Term Debt SAB Biotherapeutics|Quick Liquidity Indicator sabbiotherapeutics.com
- financial results and valuation multiples details:
SABS - Profit After Payment of Taxes|Projected Future Earnings SAB Biotherapeutics|SABS - Company Value to Net Income|Forward P/E Multiple SAB Biotherapeutics, Inc|SABS - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SAB Biotherapeutics Inc|SABS - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) SAB Biotherapeutics|SABS - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months sabbiotherapeutics.com|SABS - Earnings per share trend in current year|Earnings growth forecast for next year SAB Biotherapeutics
- total revenue and sales volume data:
Summary company analytics:SAB Biotherapeutics, Inc. SABS
The forward P/S ratio assesses the market value of an asset relative to projected revenue, allowing investors to determine the extent of the premium paid for expected sales growth. By analyzing the projected P/S multiple on the GURU.Markets platform, an investor can diagnose speculative overheating for SAB Biotherapeutics (SABS), which is critical for an antibody developer whose capitalization depends directly on clinical trial outcomes and FDA approvals.
Analysis of competing companies
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|ABVX - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio ADMA Corp ADMA|PTGX: Forward P/S Multiple|immunovant.com (IMVT) - Forward P/S Multiple|KNSA (Kiniksa) - Forward P/S Multiple|Price-to-Projected Revenue Ratio GRFS|Forward Price-to-Revenue Multiple ADPT (Adaptive Biotechnologies Corp)|CLDX (Celldex Corp) - Forward Price to Sales|Forward P/S Multiple AUPH (Aurinia Pharmaceuticals)|biocryst.com - Price-to-Projected Revenue Ratio|Vera Therapeutics - Forward P/S Multiple|Market Cap to Expected Sales Ratio Dianthus Therapeutics Inc DNTH|Pharvaris Corp (PHVS) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio AbCellera Corp (ABCL)|Forward Price-to-Revenue Multiple TRML|PGEN (precigen.com) - Price to Expected Revenue Ratio|Forward P/S Multiple PHAR|NKTR (Nektar Therapeutics Inc) - Forward Price to Sales|Forward P/S Multiple UPB (Upstream Bio Corp)|Zenas Corp (ZBIO) - Market Cap to Future Revenue Ratio|IMNM - Price-to-Projected Revenue Ratio|Forward Price to Sales GOSS (gossamerbio.com)|KALV: Forward P/S Multiple|Septerna, Inc. (SEPN) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals Inc|Savara Pharma - Future Price to Revenue|Forward P/S Multiple RIGL|ANAB - Market Cap to Future Revenue Ratio|Astria Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple enGene Holdings Inc ENGN|RAPT: Forward Price-to-Revenue Multiple|Aerovate Therapeutics Inc - Price to Expected Revenue Ratio|ACRS: Forward P/S Multiple|KYTX - Market Cap to Expected Sales Ratio|TLSA (Tiziana Life Sciences Ltd) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Cabaletta Bio Inc. (CABA)|Price-to-Projected Revenue Ratio Ventyx Bio (VTYX)|Market Cap to Expected Sales Ratio Theratechnologies, Inc|Price-to-Projected Revenue Ratio Avalo Therapeutics, Inc AVTX|Market Cap to Expected Sales Ratio eledon.com (ELDN)|Agenus Inc. - Forward P/S Multiple|CLYM - Forward P/S Multiple|ZURA: Forward P/S Multiple|ATYR (aTyr Pharmaceuticals) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Adagene Inc|Ikena Oncology, Inc. (IMA) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Shattuck Labs, Inc. (STTK)|EQ: Future Price to Revenue|Forward P/S Multiple CNTB (Connect Biopharma Holdings Limited)|Forward Price to Sales IMUX|Atara Biotherapeutics Inc - Forward P/S Multiple|IFRX - Forward P/S Multiple|X4 Pharmaceuticals, Inc. (XFOR) - Price-to-Projected Revenue Ratio|Adicet Bio, Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Celularity Inc|Forward Price-to-Revenue Multiple INmune Bio Corporation (INMB)|Forward P/S Multiple BRNS|Forward P/S Multiple kezarlifesciences.com (KZR)|Akari Therapeutics Plc - Forward Price-to-Revenue Multiple|Forward Price to Sales ENLV|Q32 Bio Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio GeoVax Corp GOVX|Edesa Biotech, Inc. (EDSA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple ibioinc.com|Price-to-Projected Revenue Ratio Carisma Therapeutics Inc|Forward Price-to-Revenue Multiple XTL Biopharmaceuticals Ltd (XTLB)|Forward Price-to-Revenue Multiple BOLT (Bolt Biotherapeutics)|Forward P/S Multiple hcwbiologics.com (HCWB)|Price-to-Projected Revenue Ratio Aptevo Therapeutics Inc. APVO|AIM: Market Cap to Projected Revenue|Aditxt Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio GRI Bio Inc|XORTX (XRTX) - Price-to-Projected Revenue Ratio|HIND - Market Cap to Expected Sales Ratio|REVB (Revelation Biosciences) - Forward P/S Multiple|Forward P/S Multiple indaptusrx.com|Forward P/S Multiple SCNI|Price-to-Projected Revenue Ratio CALI (calcimedica.com)|Affimed N.V. - Forward Price-to-Revenue Multiple|Forward Price to Sales ALLK|HOOKIPA - Forward P/S Multiple|IGMS: Price-to-Projected Revenue Ratio|ITOS: Forward P/S Multiple|OCEA - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Market Cap to Future Revenue Ratio Third Harmonic Bio Inc THRD
